- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
Patent holdings for IPC class C07D 211/62
Total number of patents in this class: 450
10-year publication summary
|
42
|
34
|
32
|
31
|
23
|
19
|
23
|
28
|
22
|
21
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 456 |
24 |
| Biogen MA Inc. | 914 |
18 |
| Novartis AG | 10721 |
15 |
| The Regents of the University of California | 20108 |
10 |
| The Broad Institute, Inc. | 1842 |
10 |
| Eisai R&D Management Co., Ltd. | 1221 |
10 |
| The Board of Trustees of the University of Illinois | 2719 |
9 |
| ChemoCentryx, Inc. | 383 |
9 |
| Bayer Cropscience AG | 2014 |
8 |
| Massachusetts Institute of Technology | 10115 |
8 |
| The General Hospital Corporation | 4770 |
8 |
| Eli Lilly and Company | 3902 |
8 |
| Boehringer Ingelheim International GmbH | 4640 |
7 |
| Bristol-myers Squibb Company | 4849 |
6 |
| Global Blood Therapeutics, Inc. | 183 |
6 |
| Intellia Therapeutics, Inc. | 213 |
6 |
| Merck Sharp & Dohme Corp. | 2190 |
5 |
| Alkermes Pharma Ireland Limited | 269 |
5 |
| Araxes Pharma LLC | 92 |
5 |
| Dainippon Sumitomo Pharma Co., Ltd. | 181 |
5 |
| Other owners | 268 |